These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16833213)

  • 1. The latest drugs on the FDA's radar.
    Waldron T
    Behav Healthc; 2006 Jun; 26(6):34-5. PubMed ID: 16833213
    [No Abstract]   [Full Text] [Related]  

  • 2. Methylphenidate transdermal system.
    Mays DA; Findling R
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
    [No Abstract]   [Full Text] [Related]  

  • 3. A slow start to the new millennium. Zyvox, Concerta and Mifeprex headline the year.
    Cornell S
    Adv Nurse Pract; 2000 Dec; 8(12):62-4. PubMed ID: 12397912
    [No Abstract]   [Full Text] [Related]  

  • 4. Clip & save: drug chart. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2010 Mar; 48(3):9-10. PubMed ID: 20302260
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2012 Mar; 50(3):11-2. PubMed ID: 22390784
    [No Abstract]   [Full Text] [Related]  

  • 8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADHD drugs and cardiovascular risk.
    Rappley MD; Moore JW; Dokken D
    N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract]   [Full Text] [Related]  

  • 10. Debate over warnings for ADHD stimulants.
    Child Health Alert; 2006 Apr; 24():1. PubMed ID: 16673500
    [No Abstract]   [Full Text] [Related]  

  • 11. Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.
    Ghanizadeh A
    J Pediatr Urol; 2008 Aug; 4(4):306-7. PubMed ID: 18644535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate.
    Elia J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 May; 6(5):343-4. PubMed ID: 17539056
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH; Donnelly C
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract]   [Full Text] [Related]  

  • 14. A new way to deliver psychiatric meds.
    Levin-Epstein M
    Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
    [No Abstract]   [Full Text] [Related]  

  • 15. Compliance with FDA recommendations for pemoline.
    Sarkis EH
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
    [No Abstract]   [Full Text] [Related]  

  • 16. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after accidental pediatric ingestions of (dextro)amphetamine and methylphenidate.
    LoVecchio F; Ozimek J; Sawyers B; Thole D
    Am J Emerg Med; 2009 Oct; 27(8):933-4. PubMed ID: 19857410
    [No Abstract]   [Full Text] [Related]  

  • 18. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
    Taéron C
    Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 20. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.